Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...

The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy ...

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

The latest update is out from Summit Therapeutics ( (SMMT) ).

The company also has a solid dividend record. Its payouts have increased by 71% in the past decade, and it currently offers a ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

Keytruda is now under threat not only from patent expiries but also from new drug candidate ivonescimab, the first to outperform it in a Phase 3 study. It shouldn't be forgotten that >$9bn p.a ...

The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab. The stock market has been pushing up Summit's stock ...